Last reviewed · How we verify
NCT05145712
Quantitative Bowel Readiness Assessment System in Predicting the Missed Detection Rate of Adenomas
NA trial testing Bowel readiness in Self Control in 263 participants. Status unknown.
30 January 2022
Quick facts
| Lead sponsor | Renmin Hospital of Wuhan University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 263 |
| Start date | 21 July 2021 |
| Primary completion | 30 January 2022 |
| Estimated completion | 20 March 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Bowel readiness
Conditions studied
- Self Control — all drugs for Self Control →
- Prospective — all drugs for Prospective →
- Interventional — all drugs for Interventional →
Sponsor
Renmin Hospital of Wuhan University
Who can join
45 and older, any sex, with Self Control or Prospective. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To verify the correlation between the proposed artificial intelligence based bowel preparation assessment system and the missed detection rate of adenomas, and to evaluate whether the system can effectively assist doctors in identifying patients who need to be re-examined by colonoscopy due to poor intestinal cleanliness.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Validation of artificial intelligence-based bowel preparation assessment in screening colonoscopy (with video).
Yao L, Xiong H, Li Q, Wang W, et al · · 2024 · cited 11× · PMID 38636818 · DOI 10.1016/j.gie.2024.04.015
Verify or expand the search:
- PubMed search for NCT05145712
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Renmin Hospital of Wuhan University trials
Trials by the same sponsor.
- NCT07587294 — Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patien · NA · not yet recruiting
- NCT07269509 — Evaluation of the Efficacy and Safety of an Intensified Strategy of Intratonsillar Immunotherapy (ITIT) for Allergic Rhi · NA · not yet recruiting
- NCT07151560 — Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in · Phase 2 · not yet recruiting
- NCT07085221 — Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock · NA · recruiting
- NCT06614985 — The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05145712 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Renmin Hospital of Wuhan University
- Last refreshed: 6 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05145712.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing